Generics Industry Outlook: 2015

  • October 2010
  • -
  • Datamonitor

About This Report
Historical and projection analysis of the entire generic drugs market from 2005 through to 2015. Strategic dynamics within the segment are broken down by firm, geography, therapy area and formulation. See how Big Pharma firms ' strategic shift away from blockbuster small molecule products will impact generic drugs firms .

What's Included in This Report?
Analyze historical and projection generic drugs sales by geography, therapy area, formulation and industry player
Analyze the relationship between the branded prescription pharmaceutical market and the generic drugs segment
Key Market Facts
The generic drugs market has developed significantly over the past decade and represents an integral element of the broader prescription pharmaceutical industry . This role as the ‘commoditizer’ of the pharmaceutical market will remain intact; however, the level of sales growth achieved by the generic drugs market in recent years will not be sustainable.

Sales growth will slow due to a fundamental change in the growth strategies implemented by branded players - Big Pharma in particular - which have become characterized by a smaller number of blockbuster launches and increased investment in biologics and vaccines.

Why Should You Buy This Report?
Assess the outlook for the generic drugs market through to 2015
Evaluate the effects of the end of Big Pharma’s blockbuster era on the generic drugs market

Table Of Contents

TABLE OF CONTENTS
ABOUT DATAMONITOR HEALTHCARE 2
About the PharmaVitae team 2
Chapter 1 About this segment report 3
PharmaVitae Explorer database 3
Chapter structure 4
Part I Executive summary 5
Main Facts 5

Introduction to the global generics drugs industry 6
Market growth projection to slow over 2009-15 13
Part III Methodology 30
Definitions 30
Forecasting methodology 30
Part IV industry analysis 36
Main Facts 36
Global generics drugs industry sales and growth rate analysis, 2005-15 37
Geographic analysis 45
Therapy area analysis 52
Formulation analysis 59
Part V Firms analysis 63
Main Facts 63
Leading generics drugs industry players 64
Teva 65
Sandoz 71
Mylan 78
Apotex 84
Hospira 90
Ranbaxy 96
Watson 102
Part VI Appendix 108
References 108
Abbreviations 108
Exchange rates 109
About Datamonitor 110
Datamonitor consulting 110
Disclaimer 112



TABLE OF TABLES
Data table 1: Exchange rates, 2010 109



TABLE OF FIGURES
Chart 1: The PharmaVitae Explorer 3
Chart 2: Global branded and generic sales and year-on-year growth rate (%), from 2005 to 2009 8
Chart 3: Top 10 specialist generics drugs players ranked by 2009 sales (US$ bn) 9
Chart 4: Example price erosion curves (US double blockbuster first-to-file and 5EU double blockbuster) 10
Chart 5: US blockbuster sales and US generic sales and year-on-year growth (%) 12
Chart 6: Global generic sales growth by region ($bn), 2005-09, 2009-12 and 2012-15 13
Chart 7: US generics drugs sales ($bn) and number of US branded blockbuster expiries, 2010-15 14
Chart 8: Pre-expiry sales for small molecule and biologics ($bn), 2010-12 and 2013-15 18
Chart 9: Volume erosion analysis: small molecules generics drugs versus MAb biosimilars 22
Chart 10: New launches projecting methodology - Illustrative example, step 1: Original Brand X 31
Chart 11: New launches projecting methodology - Illustrative example, step 2: Potential generic sales of Brand X 32
Chart 12: New launches projecting methodology - Illustrative example, step 3: Total generic sales of Brand X 33
Chart 13: New launches projecting methodology - Illustrative example, step4: Generic sales industry player split 34
Chart 14: Zoloft and sertraline generics drugs as a percentage of pre-expiry Zoloft sales, US, 2005-09 35
Chart 15: Global generics drugs industry, sales ($m) and growth rate (%), 2005-15 37
Chart 16: Global generics drugs industry, sales ($m) and growth rate (%), 2005-09 39
Chart 17: Global generics drugs industry, sales ($m) and growth rate (%), 2009-15 41
Chart 18: Global generics drugs industry, industry ed and new launch products ($m), 2005-15 44
Chart 19: Annual sales growth from industry ed and new launch products ($m), 2009-15 45
Chart 20: Global generics drugs industry by region ($m), 2005-15 46
Chart 21: Absolute sales growth by region ($m), 2005-15 47
Chart 22: Absolute growth by region ($m), 2009-15 51
Chart 23: Global generics drugs industry by therapy area ($m), 2009-15 52
Chart 24: Absolute sales growth by therapy area ($m), 2009-15 54
Chart 25: Absolute sales growth by therapy area ($m), 2009-15 57
Chart 26: Global generics drugs industry by formulation ($m), 2005-15 59
Chart 27: Absolute sales growth by formulation ($m), 2009-15 61
Chart 28: Absolute sales growth by formulation ($m), 2009-15 62
Chart 29: Global generics drugs industry by industry player ($m), 2005-15 64
Chart 30: Teva global generic sales ($m) and growth rate (%), 2009-15 66
Chart 31: Teva global generic sales ($m) industry ed and pipeline 2009-15 67
Chart 32: Teva global generic sales by therapy area ($m) 2009-15 68
Chart 33: Teva global generic sales by formulation ($m) 2009-15 69
Chart 34: Teva global generic sales ($m) by region 2009-15 70
Chart 35: Sandoz global generic sales ($m) and growth rate (%), 2009-15 73
Chart 36: Sandoz global generic sales ($m) industry ed and pipeline 2009-15 74
Chart 37: Sandoz global generic sales by therapy area ($m) 2009-15 75
Chart 38: Sandoz global generic sales by formulation ($m) 2009-15 76
Chart 39: Sandoz global generic sales ($m) by region 2009-15 77
Chart 40: Mylan global generic sales ($m) and growth rate (%), 2009-15 79
Chart 41: Mylan global generic sales ($m) industry ed and pipeline 2009-15 80
Chart 42: Mylan global generic sales by therapy area ($m) 2009-15 81
Chart 43: Mylan global generic sales by formulation ($m) 2009-15 82
Chart 44: Mylan global generic sales ($m) by region 2009-15 83
Chart 45: Apotex global generic sales ($m) and growth rate (%), 2009-15 85
Chart 46: Apotex global generic sales ($m) industry ed and pipeline 2009-15 86
Chart 47: Apotex global generic sales by therapy area ($m) 2009-15 87
Chart 48: Apotex global generic sales by formulation ($m) 2009-15 88
Chart 49: Apotex global generic sales ($m) by region 2009-15 89
Chart 50: Hospira global generic sales ($m) and growth rate (%), 2009-15 91
Chart 51: Hospira global generic sales ($m) industry ed and pipeline 2009-15 92
Chart 52: Hospira global generic sales by therapy area ($m) 2009-15 93
Chart 53: Hospira global generic sales by formulation ($m) 2009-15 94
Chart 54: Hospira global generic sales ($m) by region 2009-15 95
Chart 55: Ranbaxy global generic sales ($m) and growth rate (%), 2009-15 97
Chart 56: Ranbaxy global generic sales ($m) industry ed and pipeline 2009-15 98
Chart 57: Ranbaxy global generic sales by therapy area ($m) 2009-15 99
Chart 58: Ranbaxy global generic sales by formulation ($m) 2009-15 100
Chart 59: Ranbaxy global generic sales ($m) by region 2009-15 101
Chart 60: Watson global generic sales ($m) and growth rate (%), 2009-15 103
Chart 61: Watson global generic sales ($m) industry ed and pipeline 2009-15 104
Chart 62: Watson global generic sales by therapy area ($m) 2009-15 105
Chart 63: Watson global generic sales by formulation ($m) 2009-15 106
Chart 64: Watson global generic sales ($m) by region 2009-15 107

View This Report »

Find all the market research you need - instantly, in one place.

+1.2 Million Research Documents & Statistics +200,000 Trusted Public Sources 350 Industries With Global Coverage

24/7 Customer Support

Talk to Amrita

+1 718 303 2019

Purchase Reports From Reputable Market Research Publishers

Analyzing the Global Generics Industry 2014

Analyzing the Global Generics Industry 2014

  • $ 1 750
  • Industry report
  • May 2014
  • by Aruvian's R'search

In recent times there has been a growing focus on the generic drugs industry worldwide. The patent expiry of leading drugs in recent years and also the upcoming patent expiries has put a focus on the global ...

Calcitonin Gene-Related Peptide Receptor (CRLR) Antagonists -Pipeline Insights, 2014

Calcitonin Gene-Related Peptide Receptor (CRLR) Antagonists -Pipeline Insights, 2014

  • $ 1 250
  • Industry report
  • July 2014
  • by Delve Insight

SUMMARY DelveInsight's,“Calcitonin Gene-Related Peptide Receptor (CRLR) Antagonists-Pipeline Insights, 2014”, report provides comprehensive insights about pipeline drugs across this mechanism of action ...

Transition at Teva: Blockbuster drug Copaxone to lose patent protection in 2014

Transition at Teva: Blockbuster drug Copaxone to lose patent protection in 2014

  • $ 495
  • Industry report
  • April 2014
  • by MarketLine

Introduction In October 2013, Teva announced that it would be cutting approximately 10% of the workforce in order to cut costs. Later that month, it announced the departure of its CEO of just 18 months, ...

Global Markets For Generic Drugs

January 2014 $ 6 650

Global Hyaluronic Market 2012-2016

October 2013 $ 2 500

Global Generics, Marketline

August 2013 $ 350

ReportLinker is an award-winning market research solution that finds, filters and organizes the latest industry data so you get all the market research you need - quickly, in one place.